SuperworthDocGo price to free cash flow DCGO
Market value divided by free cash flow over the last twelve months, since 2022.
- Today, Oct 23, 2026
- n/m
- not a meaningful number
- Last meaningful
- 4.0×
- Aug 2026
- 4-year median
- 3.4×
- 4-year range
- 1.2× to 34.5×
- Peer median
- 11.8×
DocGo's price to free cash flow is not a meaningful number today: free cash flow over the last twelve months was zero, negative or not reported.
It was last meaningful in Aug 2026, at 4.0×.
On the days it had one over the last 4 years, its median was 3.4×, from 1.2× in Mar 2026 to 34.5× in Mar 2023.
Price to free cash flow over time
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2026 so far | 4.0× | 1.2× | 4.0× |
| 2025 | 1.7× | 1.3× | 12.5× |
| 2024 | 9.9× | 9.0× | 10.1× |
| 2023 | 33.6× | 22.8× | 34.5× |
| 2022 | 22.3× | 20.8× | 25.3× |
Against its peers
Companies in Healthcare nearest DocGo's size, closest first, today.
| Company | Price to free cash flow |
|---|---|
| DCGODocGo | n/m |
| NEPHNephros | n/m |
| ATNMActinium Pharmaceuticals | n/m |
| APTAlpha Pro Tech | 9.7× |
| SPROSpero Therapeutics | n/m |
| LFVNLifevantage | 11.0× |
| ICCCImmucell | 22.1× |
| KEQUKewaunee Scientific | 8.7× |
| PDEXPro DEX | 29.5× |
| PLXProtalix BioTherapeutics | 26.8× |
| NATRNatures Sunshine Products | 11.8× |
| Peer median | 11.8× |
What the price to free cash flow tells you
Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.
Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.
More on DocGo
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.